Author

Johannes Nippgen

Observed names: J. Nippgen, J.B.W. Nippgen, Johannes B.W Nippgen, Johannes B.W. Nippgen, Nippgen, J.

Observed institutions: University of California, Los Angeles, Merck KGaA, Darmstadt (Germany), Eli Lilly (United States), Washington University in St. Louis, Ghent University Hospital, Institut Jules Bordet, Centre Hospitalier Universitaire Vaudois, Baylor University Medical Center, Henry Ford Hospital, Chang Gung Memorial Hospital, Klinik und Poliklinik für Urologie, Massachusetts General Hospital, Glycotope (Germany), Taoyuan Chang Gung Memorial Hospital, Los Angeles Medical Center, Klinikum Oldenburg, Greater Poland Cancer Center, Linkou Chang Gung Memorial Hospital, Royal Marsden Hospital, Duke Medical Center, Universitair Ziekenhuis Brussel, Hôpital Ambroise-Paré, Imelda Hospital, National University Hospital, University Hospital Carl Gustav Carus, Moscow City Oncology Hospital №62, Istituto Oncologico della Svizzera Italiana, Merck Healthcare KGaA, Darmstadt (Germany), University of Virginia, Technische Universität Dresden, University of Tübingen, Ludwig-Maximilians-Universität München, Amsterdam UMC Location Vrije Universiteit Amsterdam, University of Lausanne

OpenAlex ID: A5080338388

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

2009 · Eric Van Cutsem, Claus-Henning Köhne, et al. · New England Journal of Medicine · 3,880

PDF

Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme

2008 · David A. Reardon, Karen L. Fink, et al. · Journal of Clinical Oncology · 481

Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial

2007 · E. Van Cutsem, M. Nowacki, et al. · Journal of Clinical Oncology · 313

KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience

2008 · C. Bokemeyer, I. Bondarenko, et al. · Journal of Clinical Oncology · 240

A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer

2006 · Helmut Friess, Jan M Langrehr, et al. · BMC Cancer · 125

PDF

Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway

2008 · Leticia Oliveira-Ferrer, Jessica Hauschild, et al. · Journal of Experimental & Clinical Cancer Research · 117

PDF

Cisplatin, methotrexate and bleomycin for treating advanced penile carcinoma

2006 · Oliver W. Hakenberg, Johannes B.W. Nippgen, et al. · British Journal of Urology · 116

Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (q1w): The EVEREST experience (preliminary data)

2008 · S. Tejpar, M. Peeters, et al. · Journal of Clinical Oncology · 92

A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors

2014 · E. Gabriela Chiorean, Christopher Sweeney, et al. · Cancer Chemotherapy and Pharmacology · 61

Expression of Ki‐67 in squamous cell carcinoma of the penis

2005 · Navid Berdjis, Axel Meye, et al. · British Journal of Urology · 55

Phase I/IIa trial of cilengitide (EMD121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients (pts) with newly diagnosed glioblastoma (GBM)

2007 · R. Stupp, R. Goldbrunner, et al. · Journal of Clinical Oncology · 51

A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors

2016 · A.J. Wagner, H. Kindler, et al. · Annals of Oncology · 49

PDF

Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study

2009 · Jean-Luc Raoul, Jean-Luc Van Laethem, et al. · BMC Cancer · 43

PDF

Phase I study of olaratumab in J apanese patients with advanced solid tumors

2014 · Toshihiko Doi, Yan Ma, et al. · Cancer Science · 35

PDF

Spontaneous late rupture of orthotopic detubularized ileal neobladders: report of five cases

2001 · Johannes B.W Nippgen, Oliver W Hakenberg, et al. · Urology · 32

Correlation of KRAS status (wild type [wt] vs. mutant [mt]) with efficacy to first-line cetuximab in a study of cetuximab single agent followed by cetuximab + FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC)

2008 · A. Cervantes, T. Macarulla, et al. · Journal of Clinical Oncology · 22

Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer

2020 · Alberto Sobrero, Heinz-Josef Lenz, et al. · The Oncologist · 19

PDF

Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer

2018 · Oliver W. Hakenberg, Jose Luis Perez-Gracia, et al. · European Journal of Cancer · 14

Cetuximab with irinotecan in first-line treatment of epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC): Preliminary safety results (CRYSTAL)

2006 · I. Lang, J. Zaluski, et al. · Journal of Clinical Oncology · 7

The EVEREST study: relationship between efficacy and K-RAS mutation status in patients with irinotecan-refactory MCRC treated with irinotecan and standard or escalating doses of cetuximab

2008 · Sabine Tejpar, Marc Peeters, et al. · Ghent University Academic Bibliography (Ghent University) · 4

An open-label, phase I study of cetuximab to assess the safety, efficacy and pharmacokinetics (PK) of different cetuximab regimens in patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC)

2005 · Y. Humblet, M. Peeters, et al. · Journal of Clinical Oncology · 4

Retrospective analysis of overall survival (OS) by subsequent therapy in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) receiving irinotecan ± cetuximab in the EPIC study.

2019 · Alberto F. Sobrero, Heinz-Josef Lenz, et al. · Journal of Clinical Oncology · 3

First-in-human phase I study of CetuGEX, a novel anti-EGFR monoclonal antibody (mAb) with optimized glycosylation and antibody dependent cellular cytotoxicity.

2013 · Walter Fiedler, Cristiana Sessa, et al. · Journal of Clinical Oncology · 3

A phase Ib/II study evaluating the efficacy of doxorubicin (D) with or without a human anti-PDGFRα monoclonal antibody olaratumab (IMC-3G3) in the treatment of advanced soft tissue sarcoma (STS).

2012 · William D. Tap, Brian Andrew Van Tine, et al. · Journal of Clinical Oncology · 2

Preliminary safety, efficacy, and pharmacokinetics (PK) results of the EP4 antagonist INV-1120 from a phase I study in Chinese patients with advanced solid tumors.

2023 · Chang Liu, Miao Zhang, et al. · Journal of Clinical Oncology · 1

Works count: 36

Citation count: 5,771

H-index: 17

I10-index: 18